TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32030780
Drug: A annua
Normalized name: IVA ANNUA POLLEN
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A annua sublingual immunotherapy (SLIT) for 16 weeks
Study: 36297099
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous vitamin C (HDIVC)
Study: 39418854
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT)
Study: 35513899
Drug: Once-daily fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily fixed combination of Bimatoprost 0.01%, Brimonidine 0.15%, and Timolol 0.5%
Study: 35150194
Drug: Technique A
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technique A (shallow injection/3 aliquots)
Study: 33794353
Drug: Web-based Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based Drug Management Module (DMM)
Study: 34087948
Drug: Omecamtiv mecarbil
Normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omecamtiv mecarbil (OM) 25 mg modified release (MR) tablets under fed state
Study: 34087948
Drug: Omecamtiv mecarbil
Normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omecamtiv mecarbil (OM) 37.5 mg modified release (MR) tablets under fed state
Study: 34087948
Drug: Omecamtiv mecarbil
Normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omecamtiv mecarbil (OM) 50 mg modified release (MR) tablets under fed state
Study: 34087948
Drug: Two 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 25 mg OM MR tablets
Study: 34226418
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg sugammadex
Study: 33652234
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no thermal treatment)
Study: 33444175
Drug: I-WOTCH multicomponent
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-WOTCH multicomponent self-management intervention for tapering opioid doses
Study: 34600734
Drug: BDP/FF/GB 200/12/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF/GB 200/12/25 ?g (therapeutic)
Study: 34600734
Drug: BDP/FF/GB 400/12/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF/GB 400/12/25 ?g (therapeutic)
Study: 34600734
Drug: BDP/FF/GB 800/48/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF/GB 800/48/100 ?g (supratherapeutic)
Study: 34534429
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg) plus platinum-based chemotherapy (with or without bevacizumab)
Study: 34534429
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus platinum-based chemotherapy (with or without bevacizumab)
Study: 34584851
Drug: Waitlist control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist control condition, received delayed treatment at follow-up assessment.
Study: 39660834
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy
Study: 35915056
Drug: Multi-session Cognitive
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-session Cognitive Behavioral Therapy (CBT)
Study: 38587237
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg daily
Study: 35605625
Drug: Heterologous booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heterologous booster vaccination with low dose aerosolised Ad5-nCoV (1·0×10^11 viral particles per mL; 0·1 mL)
Study: 35605625
Drug: Heterologous booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heterologous booster vaccination with high dose aerosolised Ad5-nCoV (1·0×10^11 viral particles per mL; 0·2 mL)
Study: 35605625
Drug: Homologous intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homologous intramuscular vaccination with CoronaVac (0·5 mL)
Study: 35605625
Drug: Heterologous booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heterologous booster vaccination with low dose aerosolised Ad5-nCoV
Study: 35605625
Drug: Heterologous booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heterologous booster vaccination with high dose aerosolised Ad5-nCoV
Study: 35605625
Drug: Homologous intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homologous intramuscular vaccination with CoronaVac
Study: 33087480
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine (DexM) 2 µg/kg
Study: 35562778
Drug: REALIST ORBCEL‐C
Approvals — FDA: no, EMA: no, PMDA: no
Description: REALIST ORBCEL‐C (400 × 106 cells or maximal tolerated dose in phase 1)
Study: 32224795
Drug: Single-treatment trial
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-treatment trial
Study: 37335995
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg nicotine gum
Study: 34544468
Drug: Dose Painting
Normalized name: Castellani Paint
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose Painting (DP) procedure with doses of 80, 85, and 91 Gy delivered to PTV1, PTV2, and PTV3 respectively.
Study: 34544468
Drug: Three-Dimensional Conformal
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-Dimensional Conformal Radiation Therapy (3DCRT)
Study: 34544468
Drug: Post-treatment follow-up
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment follow-up after 4 months
Study: 33471654
Drug: 200,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200,000 IU intramuscular D2
Study: 33471654
Drug: 400,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400,000 IU intramuscular D2
Study: 33471654
Drug: 600,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600,000 IU intramuscular D2
Study: 39515988
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel
Study: 35474643
Drug: Pharmacist-based coaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-based coaching (12 weekly face-to-face sessions)
Study: 33998672
Drug: BIA 10‐2474
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 10‐2474 (2.5–50 mg repeated oral doses for 10 days)
Study: 33998672
Drug: BIA 10‐2474
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 10‐2474 (50 mg repeated administration)
Study: 32683645
Drug: 30 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 months of dual antiplatelet therapy (DAPT)
Study: 34049672
Drug: 12 months
Normalized name: Elecare HMO 0-12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months of dual antiplatelet therapy (DAPT)
Study: 35700617
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (oral analgesics: acetaminophen q6h 1000 mg and NSAID, and sling if shoulder injury)
Study: 34580169
Drug: Impedance cardiography
Normalized name: FAST-PAK ANGIOGRAPHY KIT WITH VASCORAY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impedance cardiography (ICG) guided treatment strategy
Study: 38224135
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy (TRT)
Study: 36914946
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment only (control group)
Study: 35656720
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (TT)
Study: 33645176
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy (CT)
Study: 35969882
Drug: Estrogen-alone therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-alone therapy (from meta-analysis)
Study: 32086889
Drug: Step-down pharmacotherapy
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-down pharmacotherapy (n=67)
Study: 32086889
Drug: Maintaining therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintaining therapy (n=68)
Study: 34744069
Drug: Sling Suspension
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sling Suspension Therapy (SST)
Study: 34920046
Drug: High-dose TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose TXA (≥50 mg/kg)
Study: 34772753
Drug: Oral fixation
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fixation device
Study: 38418234
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy
Study: 33737614
Drug: 450 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 g/kg iso-lipid test diet
Study: 33737614
Drug: 550 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 550 g/kg iso-lipid test diet
Study: 33737614
Drug: 500 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 g/kg iso-lipid test diet
Study: 32620339
Drug: Acetaminophen (APAP)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (APAP) 3 g/d for 28 days
Study: 32444220
Drug: Allogeneic umbilical
Normalized name: Allogeneic umbilical cord mesenchymal stem cells
DrugBank: Allogeneic umbilical cord mesenchymal stem cells (DB18367)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic umbilical cord blood infusion
Study: 34287251
Drug: Traditional chemotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional chemotherapy setting
Study: 35230058
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) - 5 consecutive daily 90-minute sessions at 2.0 atmospheres absolute with 100% oxygen
Study: 33179515
Drug: Oral combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral combined estradiol (E2) and progesterone therapy
Study: 35277071
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose iron and curcumin (FS65_Curc)
Study: 35277071
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose iron and curcumin placebo (FS65_Plac)
Study: 33864725
Drug: Oral allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral allopurinol 300 mg twice daily
Study: 37159610
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation therapy (CRT)
Study: 33798310
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy (regulating menstruation and promoting pregnancy) at Baihui (GV 20), Shenting (GV 24), Guanyuan (CV 4), Sanyinjiao (SP 6), Shenshu (BL 23), Ciliao (BL 32), once a day, 5 times a week for 3 months.
Study: 33798310
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (oral administration of climen, 1 tablet a day for 21 days, stopped for 1 week as a course, required 3 consecutive courses).
Study: 34962984
Drug: Polypill plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill plus aspirin
Study: 34787762
Drug: Conventional periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional periodontal treatment associated with 10 laser applications by the ILIB‐Modified (ILIB‐M) technique
Study: 32532654
Drug: Ramelteon (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon (8 mg)
Study: 36375174
Drug: Antipsychotics
Normalized name: ANTIPSYCHOTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotics
Study: 32753699
Drug: IgG antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG antibodies against non-self glycans
Study: 32753699
Drug: IgG antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG antibodies against self glycans
Study: 39178051
Drug: Electroconvulsive Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive Therapy (ECT)
Study: 33907075
Drug: Non-Electroconvulsive Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Electroconvulsive Therapy (non-ECT)
Study: 33453383
Drug: Selenite-loaded chitosan
Normalized name: selenite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenite-loaded chitosan nanoparticles (SeChNPs) 1 g/kg diet
Study: 33453383
Drug: Selenite-loaded chitosan
Normalized name: selenite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenite-loaded chitosan nanoparticles (SeChNPs) 2 g/kg diet
Study: 33856434
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (topical ocular hypotensive medication)
Study: 32779952
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 25 mg weekly
Study: 32790845
Drug: rhTPO (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhTPO (300 U/kg once daily from days 14 to 28 after UCBT)
Study: 38942209
Drug: Cariprazine 1.5
Normalized name: cariprazine 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine 1.5 mg/d
Study: 37551609
Drug: Cariprazine 3
Normalized name: cariprazine 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine 3 mg/d
Study: 32646561
Drug: Alirocumab 150
Normalized name: alirocumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 150 mg every 2 weeks
Study: 36048465
Drug: Temperature-Controlled Radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temperature-Controlled Radiofrequency (TCRF) device treatment of the nasal valve
Study: 33023497
Drug: Interprofessional medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interprofessional medication assessment
Study: 35793990
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg
Study: 35920686
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment
Study: 34259467
Drug: Levonorgestrel 52‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 52‐mg intrauterine system
Study: 34171293
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Care (conventional medical treatment)
Study: 32104921
Drug: 2.45 GHz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.45 GHz Wi-Fi exposure with a total antenna input power of 220 mW; specific absorption rate (SAR) in cortical brain regions approximately 1-2 mW/kg.
Study: 39249590
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (control group)
Study: 32959557
Drug: Prednisone acetate
Normalized name: Prednisone acetate
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone acetate (30 mg/d for 5 days, then reduced to 10 mg/d for 1 week) and muscular injection with vitamin B12 (0.5 mg) and B1 (0.1 mg) daily, followed by oral vitamin B1 (10 mg, three times a day for 10 days).
Study: 32356074
Drug: Sham CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham CPAP therapy
Study: 35182035
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin capsule (ORMD‐0801) 8 mg
Study: 35182035
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin capsule (ORMD‐0801) 48 mg
Study: 35182035
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin capsule (ORMD‐0801) 8 mg (stage 2)
Study: 35182035
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin capsule (ORMD‐0801) 32 mg (stage 2)
Study: 35182035
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin capsule (ORMD‐0801) 48 mg (stage 2)
Study: 35182035
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin capsule (ORMD‐0801) 8-48 mg (both stages)
Study: 37858867
Drug: Oral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral therapy
Study: 34481972
Drug: Mediterranean diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean diet with additional extra virgin olive oil (40 mL daily) and pistachios (25 to 30 g daily)
Study: 33098997
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of standard doses of FOLFOX/CAPOX
Study: 33098997
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of standard doses of FOLFOX/CAPOX
Study: 32388538
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg oral dose)
Study: 33913765
Drug: Postpartum DMPA
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postpartum DMPA administration
Study: 33913765
Drug: No DMPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: No DMPA administration (Control)
Study: 35609913
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment only
Study: 32885541
Drug: E‐AR cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: E‐AR cream containing GSH‐C4 (0.1%), beta‐Glycyrrhetic (0.5%), and azelaic acids (10%) applied daily for 8 weeks
Study: 32885541
Drug: E‐AR cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: E‐AR cream
Study: 36307922
Drug: CETP inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: CETP inhibitor TA-8995 (obicetrapib)
Study: 32948577
Drug: Stem cell
Normalized name: Stem cells, apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stem cell treatments
Study: 35666852
Drug: Budesonide oral
Normalized name: budesonide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide oral suspension (BOS)
Study: 33575846
Drug: Adjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment (RT or RCT)
Study: 33575846
Drug: Adjuvant radio(chemo)therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radio(chemo)therapy (RCT and RT)
Study: 38368409
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant therapy
Study: 39311825
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion
Study: 33978187
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg elemental iron as ferrous sulfate for 12 weeks
Study: 33637837
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TaU)
Study: 33663545
Drug: Betaine supplementation
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaine supplementation (2 g/day)
Study: 35094931
Drug: Progressive tendon-loading
Normalized name: Bos taurus tendon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive tendon-loading exercise therapy
Study: 35094931
Drug: Eccentric exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eccentric exercise therapy
Study: 36205248
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg daily for 45 days
Study: 35318115
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (administered at birth, 1 month, and 6 months)
Study: 33330915
Drug: Leucine intake
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine intake ranging from 20 to 120 mg . kg‐1 . d‐1
Study: 35709830
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of donor feces
Study: 35709830
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g of donor feces
Study: 32284450
Drug: Concurrent resistance-aerobic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent resistance-aerobic training for 16 weeks, 60 min three times a week
Study: 32959481
Drug: Internet-delivered cognitive-behavioural
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive-behavioural therapy (ICBT) with brief weekly telephone support
Study: 32164773
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group doing their daily activities
Study: 35287166
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch + mini‐lozenge
Study: 35924071
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with a fixed injection flow rate of 3.5 ml/s, time was 12 s with a total of 42 ml.
Study: 38776334
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy
Study: 32732154
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (3,666 mg/day for 3 months)
Study: 33423540
Drug: Warfarin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin plus aspirin
Study: 36151529
Drug: Training GPs
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training GPs to offer treatment as the default choice using an encounter decision aid (paper or electronic).
Study: 33933894
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill
Study: 35716471
Drug: Gyejibongnyeong-Hwan (GBH)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gyejibongnyeong-Hwan (GBH) treatment for 8 weeks
Study: 35716471
Drug: Gyejibongnyeong-Hwan (GBH)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gyejibongnyeong-Hwan (GBH) treatment
Study: 36349190
Drug: Ultrasound-guided lumbar
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided lumbar plexus block (group L)